These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32409018)

  • 1. Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: A postmarketing surveillance of more than 3000 patients.
    Nakazawa M; Hara K; Komeda T; Ogura E
    J Infect Chemother; 2020 Jul; 26(7):729-735. PubMed ID: 32409018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study.
    Yokoyama T; Sakaguchi H; Ishibashi T; Shishido T; Piedra PA; Sato C; Tsuchiya K; Uehara T
    Pediatr Infect Dis J; 2020 Aug; 39(8):706-712. PubMed ID: 32433222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).
    Baker J; Block SL; Matharu B; Burleigh Macutkiewicz L; Wildum S; Dimonaco S; Collinson N; Clinch B; Piedra PA
    Pediatr Infect Dis J; 2020 Aug; 39(8):700-705. PubMed ID: 32516282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.
    Ikematsu H; Hayden FG; Kawaguchi K; Kinoshita M; de Jong MD; Lee N; Takashima S; Noshi T; Tsuchiya K; Uehara T
    N Engl J Med; 2020 Jul; 383(4):309-320. PubMed ID: 32640124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label study of the safety, pharmacokinetics, and effectiveness of a 2 mg/kg dose of baloxavir marboxil 2% granules in children <20 kg with influenza.
    Sonoyama T; Sakaguchi H; Koshimichi H; Noshi T; Tsuchiya K; Uehara T
    J Infect Chemother; 2021 Aug; 27(8):1223-1229. PubMed ID: 34045119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.
    Tejada S; Tejo AM; Peña-López Y; Forero CG; Corbella X; Rello J
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):901-918. PubMed ID: 33861168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan.
    Hirotsu N; Sakaguchi H; Fukao K; Kojima S; Piedra PA; Tsuchiya K; Uehara T
    BMC Pediatr; 2023 Jan; 23(1):35. PubMed ID: 36681802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
    Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
    N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carryover effects of baloxavir acid in human nasopharyngeal/pharyngeal swabs on infectious titer testing of influenza virus.
    Baba K; Oka R; Shano S; Omoto S; Noshi T; Shishido T; Naito A; Kawaguchi K; Ishibashi T; Uehara T
    Influenza Other Respir Viruses; 2020 May; 14(3):353-357. PubMed ID: 31994309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 years with influenza: an open-label, randomized, active-controlled trial protocol.
    Ishiguro N; Morioka I; Nakano T; Furukawa M; Tanaka S; Kinoshita M; Manabe A
    BMC Infect Dis; 2021 Aug; 21(1):777. PubMed ID: 34372769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza A in Yokohama, Japan.
    Yoshimura Y; Sasaki H; Horiuchi H; Miyata N; Kawakami C; Usuku S; Tachikawa N
    Eur J Clin Microbiol Infect Dis; 2020 Sep; 39(9):1637-1640. PubMed ID: 32291543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
    Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y
    Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes.
    Hirotsu N; Sakaguchi H; Sato C; Ishibashi T; Baba K; Omoto S; Shishido T; Tsuchiya K; Hayden FG; Uehara T; Watanabe A
    Clin Infect Dis; 2020 Aug; 71(4):971-981. PubMed ID: 31538644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.
    Li Y; Wang X; Liao Y; Zeng Y; Lin W; Zhuang W
    BMC Infect Dis; 2024 May; 24(1):446. PubMed ID: 38724914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis.
    Taieb V; Ikeoka H; Wojciechowski P; Jablonska K; Aballea S; Hill M; Hirotsu N
    Curr Med Res Opin; 2021 Feb; 37(2):225-244. PubMed ID: 33079575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.
    Shirley M
    Drugs; 2020 Jul; 80(11):1109-1118. PubMed ID: 32601915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
    Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
    Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the incidence of bleeding between baloxavir marboxil and other anti-influenza drugs among outpatients with influenza virus infection: A retrospective cohort study using an employment-based health insurance claims database in Japan.
    Hara A; Hara K; Komeda T; Ogura E; Miyazawa S; Kobayashi C; Fujiwara M; Yoshida M; Urushihara H
    Pharmacoepidemiol Drug Saf; 2022 Jun; 31(6):623-631. PubMed ID: 34881477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effectiveness of baloxavir marboxil against influenza in three seasons.
    Kakuya F; Okubo H; Fujiyasu H; Kurisawa MJ; Kinebuchi T
    Pediatr Int; 2022 Jan; 64(1):e15169. PubMed ID: 35790049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
    Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
    Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.